Last reviewed · How we verify
AZD9833
AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth.
AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, Hormone receptor-positive breast cancer in combination with CDK4/6 inhibitors.
At a glance
| Generic name | AZD9833 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor Alpha (ESR1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AZD9833 functions as a next-generation SERD that achieves rapid and sustained degradation of estrogen receptor alpha in hormone receptor-positive breast cancer cells. Unlike traditional selective estrogen receptor modulators (SERMs), SERDs eliminate the receptor protein entirely rather than simply blocking its activity, preventing both ligand-dependent and ligand-independent signaling. This mechanism overcomes some resistance mechanisms seen with aromatase inhibitors and tamoxifen.
Approved indications
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
- Hormone receptor-positive breast cancer in combination with CDK4/6 inhibitors
Common side effects
- Hot flashes
- Nausea
- Fatigue
- Vaginal dryness
- Diarrhea
Key clinical trials
- Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (PHASE3)
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (PHASE3)
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer (PHASE2)
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PHASE1, PHASE2)
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (PHASE1)
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (PHASE3)
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9833 CI brief — competitive landscape report
- AZD9833 updates RSS · CI watch RSS
- AstraZeneca portfolio CI